Advanced Therapy Medicinal Products (ATMPs) – including gene therapies, cell therapies, and tissue-engineered products – represent one of the most profound shifts in modern medicine, with ATMP clinical trials playing a critical role in translating these innovations into approved therapies. Instead of targeting downstream symptoms, these therapies aim to correct or replace the biological mechanisms underlying disease.
Over the last decade, ATMPs have evolved from experimental academic concepts into a rapidly expanding therapeutic field. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved an increasing number of cell and gene therapies, and hundreds more are currently in clinical development.
Yet translating breakthrough biology into approved therapies remains exceptionally complex. Unlike traditional pharmaceuticals, ATMP development simultaneously requires mastery of clinical science, manufacturing, regulatory strategy, and translational biology.
For biotech leaders navigating this landscape, understanding both the opportunities and the risks is critical.
Under European regulation (Regulation EC No 1394/2007), ATMPs are defined as therapies based on genes, cells, or engineered tissues. The category includes three main classes:
ATMP classification is well summarized by ATMP Sweden in the image below:
Each of these categories presents unique development challenges. Unlike small molecules, where the active substance is chemically defined, ATMPs often involve living biological systems, making characterization and consistency more difficult.
The rapid expansion of ATMPs has produced several remarkable clinical successes — but also some notable failures. Together they illustrate both the promise and the complexity of this field.
Several recently approved therapies demonstrate how transformative these technologies can be.
Examples include:
These therapies demonstrate that ATMPs can achieve outcomes that were previously impossible using conventional drugs.
However, the ATMP field has also experienced significant failures.
Notable examples include:
These experiences highlight a key lesson: scientific innovation alone does not guarantee clinical or commercial success.
Developing ATMPs presents a number of unique scientific and operational challenges. These include manufacturing and product consistency, design of ATMP clinical trials and long-term safety monitoring, as shown in the ATMPs lifecycle schematics below.
In ATMPs, the manufacturing process often defines the product itself. Small variations in cell expansion conditions, viral vector production, or purification methods can significantly influence therapeutic potency and safety.
Major challenges include:
These challenges make Chemistry, Manufacturing, and Controls (CMC) one of the most critical aspects of ATMP development.
ATMP clinical trials often target rare diseases or highly specialized patient populations, which limits traditional randomized study designs.
Developers frequently face challenges such as:
Both the FDA and EMA have acknowledged these challenges and allow adaptive trial designs, external control datasets, and natural history comparisons in appropriate situations.
Gene therapies and cell therapies may produce long-lasting or permanent biological effects, which introduces additional safety considerations.
Regulators often require long-term follow-up programs to monitor for:
The FDA recommends follow-up periods of up to 15 years for certain gene therapy products.
Recognizing the transformative potential of ATMPs, regulatory agencies have developed dedicated frameworks to support innovation while maintaining patient safety.
In the United States, the U.S. Food and Drug Administration introduced the Regenerative Medicine Advanced Therapy (RMAT) designation, designed to accelerate development of therapies addressing serious diseases with preliminary evidence of efficacy.
RMAT designation provides:
Similarly, the European Medicines Agency regulates advanced therapies through the Committee for Advanced Therapies (CAT) and supports development through the PRIME (PRIority MEdicines) scheme.
Recent regulatory discussions in both jurisdictions emphasize:
These developments reflect a growing recognition that traditional drug development frameworks do not always fit advanced therapies.
For biotech companies, selecting a CRO for ATMP clinical trials is not merely an operational choice – it is a strategic one. Several factors should be carefully evaluated.
Early-phase expertise
Many ATMP programs begin with first-in-human trials involving complex safety considerations. CRO partners should have experience managing:
Translational science integration
ATMP clinical trials rely heavily on translational endpoints. Important capabilities include:
Operational logistics
Advanced therapies often require specialized clinical logistics, including cryogenic transport and coordination with manufacturing facilities.
Regulatory strategy support
Given the evolving regulatory landscape, CROs must also support interactions with regulatory agencies and help navigate accelerated pathways such as RMAT or PRIME.
The next generation of ATMP innovation is already emerging.
Key technologies shaping the future include:
As these platforms mature, ATMPs may expand beyond rare diseases into broader indications such as cardiovascular disease, autoimmune disorders, and neurodegenerative conditions.
For biotech and pharmaceutical leaders, the opportunity is enormous — but success requires more than breakthrough science. It demands integrated expertise in clinical development, manufacturing, regulatory strategy, and operational execution.
Advanced therapies are not simply another drug modality. They represent a fundamental shift in how medicine treats disease. And for organizations able to navigate this complexity, the potential impact on patients – and on the future of medicine – is extraordinary.
Planning ATMP clinical trials in Europe? Let’s chat! Contact our business development team and schedule a call to know how APICES CRO handles the acceleration of study timelines and generation of valuable data according to plan.
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
